A Phase I Dose-Escalation Study of CUG279 in Participants With Select Advanced or Metastatic Solid Tumors
A Phase I, First-In-Human, Open-Label, Multicenter, Dose-Escalation and Expansion Study to Evaluate Safety, Pharmacokinetics, and Preliminary Efficacy of CUG279 in Participants With Select Advanced or Metastatic Solid Tumors
CUG279-P101 is a first-in-human, open-label, multicenter Phase 1 study evaluating the safety, tolerability, pharmacokinetics, immunogenicity, immune-pharmacodynamics, and preliminary antitumor activity of CUG279 in adults with select unresectable advanced or metastatic solid tumors.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Descripción detallada
The study will consist of two parts: Part A Dose Escalation and Part B Dose Expansion
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Admin Cugene
- Número de teléfono: 1(781) 893-5800
- Correo electrónico: admin@cugene.com
Ubicaciones de estudio
-
-
Virginia
-
Fairfax, Virginia, Estados Unidos, 22031
- Reclutamiento
- NEXT Virginia
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Signed and dated informed consent.
- Histologically or cytologically confirmed selected locally advanced or metastatic solid tumor.
- At least 1 measurable lesion according to RECIST v1.1.
- Progressed after, intolerant to, declined, or not considered a candidate for available standard-of-care (SoC) therapy.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
- Adequate cardiovascular, hematologic, renal, hepatic, and coagulation function.
- Life expectancy of ≥3 months.
- Female participants must not be pregnant or breastfeeding. Male participants with female partners of childbearing potential must agree to use effective contraception as specified in the protocol.
Exclusion Criteria
- Rapidly progressing disease or disease requiring urgent alternative medical intervention.
- Recent or concurrent malignancy, except certain adequately treated or low-risk malignancies as specified in the protocol.
- Prior anticancer, investigational, radiation, or immunomodulatory therapy within protocol-specified washout periods, or prior IL-2/IL-15-based therapy.
- Concurrent participation in another interventional therapeutic clinical trial.
- Active or clinically significant CNS disease, including symptomatic CNS metastases or leptomeningeal disease, except as specified in the protocol.
- Clinically significant autoimmune disease, immunodeficiency, requirement for systemic immunosuppressive therapy, or history of severe immune-mediated adverse events.
- Unresolved clinically significant toxicities from prior anticancer therapy.
- Clinically significant cardiovascular, thromboembolic, pulmonary, hepatic, or gastrointestinal disease.
- Active or clinically significant infection except as specified in the protocol.
- Recent major surgery or trauma, or prior allogeneic hematopoietic stem cell, bone marrow, or solid organ transplantation.
- Known hypersensitivity or significant allergic reaction to biologics or its components.
- Recent vaccination, except as permitted by the protocol.
- Any medical, psychological, social, or other condition that, in the Investigator's opinion, may increase risk, interfere with study participation, or confound interpretation of study results
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación Secuencial
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Part A Dose Escalation
CUG279 will be administered at multiple ascending dose levels |
CUG279 will be administered intravenously according to the protocol |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence of dose limiting toxicities (DLTs)
Periodo de tiempo: From the first dose up to 21 days post-dose
|
The number and percentage of participants with DLTs will be assessed according to the protocol-specified DLT criteria in Part A. |
From the first dose up to 21 days post-dose
|
|
Incidence and severity of treatment-emergent adverse events (TEAEs)
Periodo de tiempo: From first dose through 90 days after the last dose
|
The number and percentage of participants with TEAEs will be assessed. AEs will be graded according to NCI-CTCAE Version 6.0. |
From first dose through 90 days after the last dose
|
|
Incidence of serious adverse events (SAEs)
Periodo de tiempo: From first dose through 90 days after the last dose
|
The number and percentage of participants with SAEs will be assessed. |
From first dose through 90 days after the last dose
|
|
Clinically significant changes in safety laboratory parameters from baseline
Periodo de tiempo: From first dose through 90 days after the last dose
|
Clinically significant changes from baseline in safety laboratory parameters will be assessed. Applicable abnormalities will be graded according to NCI-CTCAE Version 6.0 |
From first dose through 90 days after the last dose
|
|
Clinically significant changes in electrocardiogram (ECG) findings from baseline
Periodo de tiempo: From first dose through 90 days after the last dose
|
Clinically significant changes from baseline in ECGs will be assessed. Applicable abnormalities will be graded according to NCI-CTCAE Version 6.0 |
From first dose through 90 days after the last dose
|
|
Clinically significant changes in vital signs from baseline
Periodo de tiempo: From first dose through 90 days after the last dose
|
Clinically significant changes from baseline in vital signs will be assessed. Applicable abnormalities will be graded according to NCI-CTCAE Version 6.0. |
From first dose through 90 days after the last dose
|
|
Incidence of TEAEs leading to dose modifications
Periodo de tiempo: From the first dose through the last dose; up to 1 year
|
The number and percentage of participants with TEAEs leading to CUG279 dose modification will be assessed. |
From the first dose through the last dose; up to 1 year
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Maximum observed plasma concentration (Cmax) of CUG279
Periodo de tiempo: From first dose through 90 days after the last dose
|
The maximum observed plasma concentration (Cmax) of CUG279 will be determined from plasma concentration-time data |
From first dose through 90 days after the last dose
|
|
Trough plasma concentrations (Ctrough) of CUG279
Periodo de tiempo: From first dose through 90 days after the last dose
|
The trough plasma concentration (Ctrough) of CUG279 will be determined from plasma samples collected immediately before the next scheduled dose |
From first dose through 90 days after the last dose
|
|
Area under the concentration-time curve (AUC) of CUG279
Periodo de tiempo: From first dose through 90 days after the last dose
|
The area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC0-last) of CUG279 will be calculated using plasma concentration-time data. |
From first dose through 90 days after the last dose
|
|
Terminal half-life (T1/2) of CUG279
Periodo de tiempo: From first dose through 90 days after the last dose
|
The terminal elimination half-life (t½) of CUG279 will be determined from plasma concentration-time data |
From first dose through 90 days after the last dose
|
|
Systemic clearance (CL) of CUG279
Periodo de tiempo: From first dose through 90 days after the last dose
|
The systemic clearance (CL) of CUG279 will be determined from plasma concentration-time data |
From first dose through 90 days after the last dose
|
|
Volume of distribution (Vz) of CUG279
Periodo de tiempo: From first dose through 90 days after the last dose
|
The volume of distribution (Vz) of CUG279 will be determined from plasma concentration-time data. |
From first dose through 90 days after the last dose
|
|
Incidence of anti-CUG279 antibodies (ADA)
Periodo de tiempo: From first dose through 90 days after the last dose
|
Number and percentage of participants with treatment-emergent or treatment-enhanced anti-CUG279 antibodies will be determined. |
From first dose through 90 days after the last dose
|
|
Incidence of anti-CUG279 neutralizing antibodies (NAb)
Periodo de tiempo: From first dose through 90 days after the last dose
|
Number and percentage of participants with neutralizing anti-CUG279 antibodies will be determined |
From first dose through 90 days after the last dose
|
|
Objective response rate (ORR)
Periodo de tiempo: From the first dose through study completion or until disease progression; up to 1 year
|
Percentage of participants whose best overall response is a confirmed complete response (CR) or partial response (PR) will be determined, per RECIST v1.1. |
From the first dose through study completion or until disease progression; up to 1 year
|
|
Disease control rate (DCR)
Periodo de tiempo: From the first dose through study completion or until disease progression; up to 1 year
|
Percentage of participants whose best overall response is CR, PR, or stable disease (SD) will be determined, per RECIST v1.1. |
From the first dose through study completion or until disease progression; up to 1 year
|
|
Time to response (TTR)
Periodo de tiempo: From the first dose through study completion or until disease progression; up to 1 year
|
Time from the first dose of CUG279 to the first documented CR or PR will be determined, per RECIST v1.1 |
From the first dose through study completion or until disease progression; up to 1 year
|
|
Duration of response (DoR)
Periodo de tiempo: From the first dose through study completion or until disease progression; up to 1 year
|
Time from first documented CR or PR to disease progression will be determined per RECIST v1.1. |
From the first dose through study completion or until disease progression; up to 1 year
|
|
Best overall response (BOR)
Periodo de tiempo: From the first dose through study completion or until disease progression; up to 1 year
|
Best confirmed overall tumor response recorded from the first dose until disease progression or the end of efficacy assessment will be determined, per RECIST v1.1. |
From the first dose through study completion or until disease progression; up to 1 year
|
|
Progression-free survival (PFS)
Periodo de tiempo: From the first dose through study completion or until disease progression; up to 1 year
|
Time from the first dose of CUG279 to radiographic disease progression will be determined, per RECIST v1.1. |
From the first dose through study completion or until disease progression; up to 1 year
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
Otros números de identificación del estudio
- CUG279-P101
- IND 179862 (U.S. FDA IND) (Otro identificador: FDA)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .